Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
21-40 of 1,694 trials

Multiple Myeloma: Isatuximab and Lenalidomide Study

We are comparing two treatment plans for newly diagnosed low-risk multiple myeloma patients to see which is more effective in reducing cancer cells. This study aims to understand the best approach for long-term patient health.

Multiple Myeloma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Prostate Cancer: Abemaciclib with Abiraterone

We are studying whether adding abemaciclib to standard treatment improves outcomes for men with prostate cancer that has spread and is responsive to hormonal therapy. The trial also evaluates safety and patient quality of life.

High-Risk Metastatic Hormone-Sensitive Prostate CancerConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Myelodysplastic Syndrome: Oral Azacitidine Study

We are studying whether Oral Azacitidine, combined with best supportive care, is more effective than a placebo for patients with low- or intermediate-risk MDS. The goal is to see if it improves blood counts and reduces the need for blood transfusions.

Myelodysplastic Syndromes (MDS)>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesHematology

Fabry Disease: Migalastat for Kidney Impairment

We are studying the safety and how the body processes migalastat in people with Fabry disease and severe kidney impairment on dialysis. This research aims to ensure the right dosing for these patients.

Fabry Disease>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyInternal MedicineNephrology

MOG Antibody Disease: Azathioprine Study

We are testing whether azathioprine can help prevent relapses in adults with MOG antibody-associated disease after their first attack. The study also looks at safety and quality of life for participants.

Anti-Myelin-Associated Glycoprotein Antibodies Positive>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Advanced Breast Cancer: ARV-471 vs Fulvestrant

We are studying a new medication, ARV-471, to see if it works better than fulvestrant for patients with advanced estrogen receptor-positive, HER2-negative breast cancer. This trial is for those whose cancer has progressed after prior treatments.

Advanced Breast CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Prostate Cancer: Lutetium-177 vs. Standard Treatments

We are comparing a new treatment called Lutetium-177 with standard medications for men with metastatic hormone-sensitive prostate cancer. The goal is to see which option better delays disease progression and improves survival.

Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyUrology

Waldenström’s Macroglobulinemia: Venetoclax with Rituximab

We are studying whether the combination of Venetoclax and Rituximab is more effective than standard treatments for patients with Waldenström’s Macroglobulinemia. This research aims to find better options for managing this condition.

Waldenström's Macroglobulinemia1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Chronic Wet Cough in Children: The AMIC Study

We are investigating whether antibiotics can help children with chronic wet cough and how different treatment durations affect their recovery. The study also looks at the role of gut and airway bacteria in their health.

Chronic Wet Cough in Young Children6-12 monthsMonitoring phase (IV)Standard MedicinesInfectious DiseasesPulmonology

Prostate Medication and Gut Health Study

We are investigating how prostate treatments affect gut bacteria and how these bacteria may influence treatment responses in men with BPH and prostate cancer.

Prostate CancerBenign Prostate Hyperplasia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineUrology

Ikervis for Atopic Keratoconjunctivitis

We are studying whether Ikervis, applied four times a day, can effectively treat atopic keratoconjunctivitis. This trial aims to see how well it works compared to a placebo.

Atopic Keratoconjunctivitis3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementOphthalmology

MRSA Treatment: Povidone Iodine Nasal Kit

We are evaluating a nasal decolonization kit with povidone iodine for patients with MRSA. The study aims to see how well it reduces MRSA levels and how patients feel about using it.

MRSA Infection>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesDermatologyInfectious Diseases

Oligometastatic Solid Cancer: SBRT with ATRA Support

We are studying a new radiation therapy combined with a drug to support the immune system in patients with oligometastatic solid cancer. This trial aims to evaluate safety and how well the treatment works.

Oligometastatic Solid Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Chronic Kidney Disease: Amiloride Treatment Study

We are investigating whether the diuretic amiloride can help protect kidney function in people with chronic kidney disease. The study looks at its effects on kidney health and inflammation.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Systemic Lupus Erythematosus: Deucravacitinib Study

We are evaluating a new medication, deucravacitinib, for individuals with active systemic lupus erythematosus. The study aims to determine if it is more effective than a placebo in reducing disease symptoms and improving overall health.

Active Systemic Lupus Erythematosus1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementRheumatology

HER2+ Breast Cancer: Tucatinib with Oral Etoposide and Trastuzumab

We are studying a new treatment combining tucatinib, oral etoposide, and trastuzumab for patients with metastatic HER2+ breast cancer who have not responded to prior therapies. The goal is to see if this combination improves treatment outcomes and safety.

Metastatic HER2+ Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Salivary Duct Carcinoma: Dutasteride with Combined Androgen Blockade

We are studying whether adding dutasteride to standard therapy helps patients with recurrent or metastatic salivary duct carcinoma. The trial also looks at safety and quality of life for those receiving this new treatment.

Salivary Duct CarcinomaEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Geographic Atrophy: JNJ-81201887 Treatment Study

We are examining the long-term safety and tolerability of JNJ-81201887 for people with geographic atrophy from age-related macular degeneration. This study follows participants from earlier trials to gather more information.

Geographic Atrophy>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteOphthalmology

Advanced Breast Cancer: Ribociclib Study

We are examining how well Ribociclib works for patients with advanced breast cancer and what factors may affect its effectiveness. The study also looks at quality of life and any side effects experienced during treatment.

Hormone Receptor Positive HER2 Negative Breast Cancer>2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Multiple Myeloma: Linvoseltamab Treatment Study

We are investigating the safety and effectiveness of linvoseltamab in patients with newly diagnosed multiple myeloma who have not yet received treatment. This study will help us understand how well this new therapy works for different patient groups.

Multiple MyelomaEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology